For research use only. Not for therapeutic Use.
Voruciclib（Cat No.:I010046）is a selective inhibitor of cyclin-dependent kinases (CDKs), specifically targeting CDK9, CDK4, and CDK6. It is primarily studied for its potential in treating hematological malignancies and solid tumors by disrupting the cell cycle and promoting apoptosis in cancer cells. Voruciclib has shown promise in preclinical and clinical trials, often in combination with other therapies to enhance its antitumor effects. By inhibiting CDK activity, it can also modulate transcriptional regulation, further influencing cancer cell survival and proliferation. Ongoing research aims to optimize its use and assess its effectiveness in various cancer types.
| Catalog Number | I010046 |
| CAS Number | 1000023-04-0 |
| Synonyms | P1446A05; P1446A-05; P1446A 05; Voruciclib.;2-(2-Chloro-4-(trifluoromethyl)phenyl)-5,7-dihydroxy-8-((2R,3S)-2-(hydroxymethyl)-1-methylpyrrolidin-3-yl)-4H-1-benzopyran-4-one |
| Molecular Formula | C22H19ClF3NO5 |
| Purity | ≥95% |
| Target | CDK4 inhibitor |
| Solubility | Soluble in DMSO, not in water |
| Storage | Store at -20°C |
| IUPAC Name | 2-[2-chloro-4-(trifluoromethyl)phenyl]-5,7-dihydroxy-8-[(2R,3S)-2-(hydroxymethyl)-1-methylpyrrolidin-3-yl]chromen-4-one |
| InChI | InChI=1S/C22H19ClF3NO5/c1-27-5-4-12(14(27)9-28)19-15(29)7-16(30)20-17(31)8-18(32-21(19)20)11-3-2-10(6-13(11)23)22(24,25)26/h2-3,6-8,12,14,28-30H,4-5,9H2,1H3/t12-,14+/m1/s1 |
| InChIKey | MRPGRAKIAJJGMM-OCCSQVGLSA-N |
| SMILES | CN1CC[C@H]([C@@H]1CO)C2=C(C=C(C3=C2OC(=CC3=O)C4=C(C=C(C=C4)C(F)(F)F)Cl)O)O |
| Reference | </br>1:Eliades P, Miller DM, Miao B, Kumar R, Taylor M, Buch S, Srinivasa SP, Flaherty KT, Tsao H. A novel multi-CDK inhibitor P1446A-05 restricts melanoma growth and produces synergistic effects in combination with MAPK pathway inhibitors. Cancer Biol Ther. 2016 Jan 25:0. [Epub ahead of print] PubMed PMID: 26810603.</br>2:Paiva C, Godbersen JC, Soderquist RS, Rowland T, Kilmarx S, Spurgeon SE, Brown JR, Srinivasa SP, Danilov AV. Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells. PLoS One. 2015 Nov 25;10(11):e0143685. doi: 10.1371/journal.pone.0143685. eCollection 2015. PubMed PMID: 26606677; PubMed Central PMCID: PMC4659573. |
